Clinical Trials in the National Cancer Institute's Database
BLADDER CANCER
Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 870 locations
Primary IDA031501
Secondary IDsNCI-2017-01425
ClinicalTrials.gov IDNCT03244384
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-Cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 525 locations
Primary ID A031702
Secondary IDs NCI-2019-01266
ClinicalTrials.gov ID NCT03866382
Testing the Addition of An Anti-Cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 350 locations
Primary ID A031803
Secondary IDs NCI-2019-07573
ClinicalTrials.gov ID NCT04164082
Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Invasive Bladder Urothelial Cancer
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 351 locations
Primary ID A031701
Secondary IDs NCI-2018-01531
ClinicalTrials.gov ID NCT03609216
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 196 locations
Primary ID S1806
Secondary IDs NCI-2018-03264
ClinicalTrials.gov ID NCT03775265
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 27 locations
Primary ID SGN22E-002
Secondary IDs NCI-2017-01927, MK-3475-869
ClinicalTrials.gov ID NCT03288545
Tazemetostat and Pembrolizumab in Treating Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 18 locations
Primary ID 10183
Secondary IDs NCI-2019-01035, ETCTN 10183
ClinicalTrials.gov ID NCT03854474
Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 19 locations
Primary ID QBGJ398-302
Secondary IDs NCI-2020-00610, 2019-003248-63
ClinicalTrials.gov ID NCT04197986
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 14 locations
Primary ID CA209-901
Secondary IDs NCI-2017-02285, 2016-003881-14
ClinicalTrials.gov ID NCT03036098
COLORECTAL CANCER
Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer, SOLARIS Trial
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 878 locations
Primary ID A021703
Secondary IDs NCI-2019-01034
ClinicalTrials.gov ID NCT04094688
Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed By Surgery
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 741 locations
Primary ID S1613
Secondary IDs NCI-2016-01422
ClinicalTrials.gov ID NCT03365882
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 901 locations
Primary ID A021502
Secondary IDs NCI-2016-01417
ClinicalTrials.gov ID NCT02912559
Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 28 locations
Primary ID 10181
Secondary IDs NCI-2018-01463, NCI-10181
ClinicalTrials.gov ID NCT03592641
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 28 locations
Primary ID XL184-021
Secondary IDs NCI-2017-01455
ClinicalTrials.gov ID NCT03170960
Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 22 locations
Primary ID SGNTUC-017
Secondary IDs NCI-2020-01033, ACCRU-GI-1617, NCI-2017-01107, P30CA015083
ClinicalTrials.gov ID NCT03043313
Circulating Tumor DNA Testing In Predicting Treatment For Patients With Stage IIA Colon Cancer After Surgery, COBRA Trial
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 684 locations
Primary ID NRG-GI005
Secondary IDs NCI-2019-01068
ClinicalTrials.gov ID NCT04068103
Transanal Total Mesorectal Excision With Laparoscopic Assistance in Treating Patients With Rectal Cancer
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 12 locations
Primary ID 16-2009
Secondary IDs NCI-2017-01497
ClinicalTrials.gov ID NCT03144765
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 12 locations
Primary ID CPI-006-001
Secondary IDs NCI-2018-02296
ClinicalTrials.gov ID NCT03454451
A Study of NKTR-262 in Combination With Bempegaldesleukin (NKTR-214) and With Bempegaldesleukin Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 15 locations
Primary ID 17-262-01
Secondary IDs NCI-2018-00619, 2018-004625-84
ClinicalTrials.gov ID NCT03435640
HEAD & NECK CANCER
Radiation Therapy with or without Cisplatin in Treating Patients with Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 460 locations
Primary ID EA3132
Secondary IDs NCI-2015-01911
ClinicalTrials.gov ID NCT02734537
De-intensified Radiation Therapy with Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients with Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 272 locations
Primary ID NRG-HN005
Secondary IDs NCI-2019-03015
ClinicalTrials.gov ID NCT03952585
Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin with Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 233 locations
Primary ID NRG-HN007
Secondary IDs NCI-2020-04581
ClinicalTrials.gov ID NCT04458909
Radiation Therapy with Durvalumab or Cetuximab in Treating Patients with Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 225 locations
Primary ID NRG-HN004
Secondary IDs NCI-2017-01522
ClinicalTrials.gov ID NCT03258554
Individualized Treatment in Treating Patients with Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 166 locations
Primary ID NRG-HN001
Secondary IDs NCI-2014-00635, NCT02179164, s16-00025, RTOG-1305
ClinicalTrials.gov ID NCT02135042
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 195 locations
Primary ID RTOG-1216
Secondary IDs NCI-2013-00500, NCT04411121
ClinicalTrials.gov ID NCT01810913
LUNG CANCER
Crizotinib in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Status: Active
Phase III
Age: 18 years and over
Gender: Male or Female
Location: 1340 locations
Primary ID E4512
Secondary IDs NCI-2014-01507, s16-02072
Clinicaltrials.gov ID NCT02201992
Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Active
Phase II
Age: 18 years and over
Gender: Male or Female
Location: 1185 locations
Primary ID EAY131
Secondary IDs NCI-2015-00054
Clinicaltrials.gov ID NCT02465060
Durvalumab and Tremelimumab in Treating Patients with Recurrent Stage IV Lung Cancer (A Lung-MAP Treatment Trial)
Status: Active
Phase II
Age: Not specified
Gender: Male or Female
Location: 1041 locations
Primary ID S1400F
Secondary IDs NCI-2016-01597, NCT02154490
Clinicaltrials.gov ID NCT03373760
Erlotinib Hydrochloride in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
Status: Active
Phase III
Age: 18 years and over
Gender: Male or Female
Location: 1291 locations
Primary ID A081105
Secondary IDs NCI-2014-01508,
s16-02079, CALGB A081105
Clinicaltrials.gov ID NCT02193282
Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Status: Active
Phase II
Age: 18 years and over
Gender: Male or Female
Location: 839 locations
Primary ID S1609
Secondary IDs NCI-2016-01041
Clinicaltrials.gov ID NCT02834013
MELANOMA
A Study to Compare the Administration of Pembrolizumab after Surgery Versus Administration both before and after Surgery for High-Risk Melanoma
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 758 locations
Primary ID S1801
Secondary IDs NCI-2018-02107
ClinicalTrials.gov ID NCT03698019
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients with Stage III-IV BRAFV600 Melanoma
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 722 locations
Primary ID EA6134
Secondary IDs NCI-2014-01747
ClinicalTrials.gov ID NCT02224781
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 525 locations
Primary ID EA6141
Secondary IDs NCI-2014-02674
ClinicalTrials.gov ID NCT02339571
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients with Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 254 locations
Primary ID EA6192
Secondary IDs NCI-2020-04463
ClinicalTrials.gov ID NCT04462406
PROSTATE CANCER
Abiraterone Acetate and Antiandrogen Therapy with or without Cabazitaxel and Prednisone in Treating Patients with Metastatic, Castration-Resistant Prostate Cancer Previously Treated with Docetaxel
Status: Active
Age: 18 years and over
Gender: Male
Location: 642 locations
Primary ID EA8153
Secondary IDs NCI-2017-00389
ClinicalTrials.gov ID NCT03419234
Standard Systemic Therapy with or without Definitive Treatment in Treating Participants with Metastatic Prostate Cancer
Status: Active
Age: 18 years and over
Gender: Male
Location: 249 locations
Primary ID S1802
Secondary IDs NCI-2018-01738
ClinicalTrials.gov ID NCT03678025
Antiandrogen Therapy and Radiation Therapy with or without Docetaxel in Treating Patients with Prostate Cancer That Has Been Removed by Surgery
Status: Active
Age: 18 years and over
Gender: Male
Location: 236 locations
Primary ID NRG-GU002
Secondary IDs NCI-2016-00963
ClinicalTrials.gov ID NCT03070886
Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients with Stage IIA-B Prostate Cancer
Status: Active
Age: 18 years and over
Gender: Male
Location: 217 locations
Primary ID NRG-GU005
Secondary IDs NCI-2017-01398
ClinicalTrials.gov ID NCT03367702
THYROID CANCER
Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer
Status: Active
Age: 12 years and over
Gender: Male or Female
Location: 27 locations
Primary ID LOXO-RET-17001 /J2G-OX-JZJA
Secondary IDs NCI-2017-00976, 2017-000800-59, LOXO-RET-17001
ClinicalTrials.gov ID NCT03157128
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy
Status: Active
Age: 16 years and over
Gender: Male or Female
Location: 15 locations
Primary ID XL184-311
Secondary IDs NCI-2018-03334
ClinicalTrials.gov ID NCT03690388
Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 13 locations
Primary ID 10240
Secondary IDs NCI-2019-02220
ClinicalTrials.gov ID NCT03914300
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
Status: Active
Age: 12 years and over
Gender: Male or Female
Location: 15 locations
Primary ID 17478
Secondary IDs NCI-2020-00277, 2019-001978-28, J2G-MC-JZJB
ClinicalTrials.gov ID NCT04211337
Vemurafenib plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 7 locations
Primary ID 20-053
Secondary IDs NCI-2020-05188
ClinicalTrials.gov ID NCT04462471